Baergic Bio, Inc. | Fortress Biotech Partner Company

Forward Looking Statements

This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; government regulation; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the SEC filings of Fortress Biotech, Inc. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

BAER-101 Overview

1. Licensed from AstraZeneca, BAER-101 (formerly known as AZD7325), is a high affinity, selective modulator of GABAα receptor system

2. Selective positive allosteric modulator (PAM) for GABAα2/3, minimizing adverse events that are typically seen with benzodiazepines, which are non-selective agonists

3. Established safety profile – well tolerated in early clinical trials (over 500 patients)

GABA(α) – Importance of Selectivity

GABA(α) Subtypes

Alpha 1   Sedating effects/tolerance
Alpha 2   anxiolytic/anti convulsant
Alpha 3   anxiolytic/anti convulsant
Alpha 5   cognitive dulling

Benzodiazepines

Non selective agonist at alpha 1, 2, 3, 5

BAER-101

Selective agonist at alpha 2, 3

GABA$_A$ receptor

Jacob et al., Nature Reviews Neuroscience, 2008

Addressable Market: Refractory Epilepsy

BAER-101 will target areas of unmet need where chronic use of a selective GABAα PAM is impactful, including Refractory Epilepsy

Refractory Epilepsy

- Epilepsy is among the most prevalent neurological disorders, affecting ~1% of the world population (~3mm in the US)

- ~30% of patients are not adequately controlled by standard of care

- A significant factor behind refractory patients is non compliance as result of significant side effects from non specific drugs

- BAER 101's unique drug profile can potentially provide an alternative treatment option for this significant unmet need

Finalization of pre-clinical proof-of-concept data for BAER-101 to support IND in Refractory Epilepsy anticipated in 1H of 2020